Index RUT
P/E -
EPS (ttm) -2.85
Insider Own 16.83%
Shs Outstand 138.39M
Perf Week 0.45%
Market Cap 4.43B
Forward P/E -
EPS next Y -2.68
Insider Trans -0.72%
Shs Float 119.08M
Perf Month 23.64%
Income -419.65M
PEG -
EPS next Q -0.62
Inst Own 84.17%
Short Float 7.57%
Perf Quarter 36.59%
Sales 1.27M
P/S 3484.31
EPS this Y -139.57%
Inst Trans -0.74%
Short Ratio 8.14
Perf Half Y 47.19%
Book/sh 9.69
P/B 3.19
EPS next Y -5.70%
ROA -29.89%
Short Interest 9.01M
Perf Year 39.11%
Cash/sh 6.26
P/C 4.94
EPS next 5Y -
ROE -32.61%
52W Range 14.56 - 32.13
Perf YTD 44.04%
Dividend Est. -
P/FCF -
EPS past 5Y -21.99%
ROI -29.39%
52W High -3.80%
Beta 1.37
Dividend TTM -
Quick Ratio 12.46
Sales past 5Y 264.19%
Gross Margin -570.72%
52W Low 112.29%
ATR (14) 1.17
Dividend Ex-Date -
Current Ratio 12.46
EPS Y/Y TTM -173.06%
Oper. Margin -39085.40%
RSI (14) 77.48
Volatility 3.32% 4.39%
Employees 445
Debt/Eq 0.04
Sales Y/Y TTM -99.63%
Profit Margin -33121.86%
Recom 1.13
Target Price 39.77
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q -145.07%
Payout -
Rel Volume 1.80
Prev Close 31.05
Sales Surprise -100.00%
EPS Surprise 13.96%
Sales Q/Q -100.00%
Earnings Aug 01 BMO
Avg Volume 1.11M
Price 30.91
SMA20 15.79%
SMA50 25.85%
SMA200 49.69%
Trades
Volume 1,997,773
Change -0.45%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Initiated
Citigroup
Buy
$32
Nov-20-23 Resumed
JP Morgan
Overweight
$28
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$85 → $35
Sep-06-23 Initiated
B. Riley Securities
Buy
$38
Jan-30-23 Initiated
SVB Securities
Outperform
$50
Dec-05-22 Initiated
Cowen
Outperform
Nov-02-22 Upgrade
BTIG Research
Neutral → Buy
$38
Nov-02-22 Initiated
BofA Securities
Buy
$40
Jun-23-22 Initiated
Berenberg
Buy
$39
Dec-10-21 Resumed
Raymond James
Mkt Perform
Sep-21-21 Initiated
Oppenheimer
Outperform
$85
Sep-01-21 Initiated
SMBC Nikko
Outperform
$78
May-18-21 Initiated
UBS
Buy
$70
Feb-26-21 Reiterated
H.C. Wainwright
Buy
$80 → $95
Feb-10-21 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$105
Nov-11-20 Reiterated
H.C. Wainwright
Buy
$65 → $80
Oct-16-20 Downgrade
BTIG Research
Buy → Neutral
Sep-14-20 Resumed
JP Morgan
Overweight
$35
Aug-20-20 Reiterated
H.C. Wainwright
Buy
$28 → $45
Mar-13-20 Upgrade
Evercore ISI
In-line → Outperform
$20
Show Previous Ratings
Sep-16-24 11:22AM
Sep-04-24 08:15AM
Sep-03-24 08:00AM
Aug-19-24 10:13AM
Aug-14-24 02:00PM
09:55AM
Loading…
Aug-06-24 09:55AM
Aug-01-24 06:45AM
Jul-23-24 06:13AM
Jul-16-24 03:19PM
(Investor's Business Daily)
Jul-08-24 07:09PM
Jun-28-24 08:37AM
Jun-24-24 09:07AM
Jun-12-24 07:00AM
Jun-06-24 11:31AM
Jun-04-24 01:17PM
08:00AM
Loading…
Jun-03-24 08:00AM
May-09-24 07:00AM
May-08-24 11:17AM
09:16AM
08:20AM
May-07-24 10:56PM
05:56PM
04:01PM
May-01-24 08:00AM
Apr-09-24 08:46AM
Apr-08-24 08:00AM
Mar-28-24 11:30AM
Mar-19-24 08:30AM
Feb-28-24 08:08AM
Feb-27-24 08:31AM
08:05AM
Loading…
08:05AM
08:00AM
06:53AM
Feb-16-24 08:39AM
08:22AM
07:13AM
Feb-07-24 08:00AM
Feb-01-24 08:00AM
Jan-31-24 11:04PM
Jan-26-24 10:00AM
Jan-11-24 01:11PM
Jan-09-24 08:44AM
Jan-08-24 08:00AM
06:30AM
06:30AM
Jan-02-24 01:57PM
Dec-22-23 06:22AM
Dec-21-23 09:55AM
Dec-07-23 11:31AM
Nov-27-23 07:01PM
09:55AM
Nov-21-23 06:00AM
Nov-07-23 05:50PM
04:01PM
Nov-06-23 09:55AM
Nov-01-23 10:30AM
Oct-19-23 10:30AM
Oct-06-23 04:41AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-09-23 03:59PM
Sep-07-23 11:30AM
Aug-30-23 08:30AM
Aug-29-23 09:00AM
Aug-11-23 11:36AM
Aug-10-23 12:02PM
06:03AM
Aug-08-23 06:05PM
04:01PM
Jun-29-23 05:13AM
Jun-27-23 02:23PM
Jun-26-23 10:00AM
(The Wall Street Journal)
Jun-21-23 03:21PM
06:00AM
Jun-20-23 04:20PM
07:00AM
Jun-09-23 11:30AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-05-23 06:15PM
May-31-23 01:30PM
May-16-23 06:00AM
May-15-23 04:31PM
May-09-23 01:24PM
May-08-23 05:15PM
04:01PM
May-04-23 01:21PM
May-01-23 10:00AM
Apr-27-23 10:02AM
Apr-14-23 07:03AM
Apr-12-23 08:00AM
Apr-10-23 08:00AM
Apr-04-23 05:12AM
Mar-29-23 11:30AM
Mar-04-23 07:35AM
Feb-28-23 09:01AM
Feb-27-23 05:35PM
04:01PM
Feb-23-23 11:15AM
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SATO VICKI L Director Sep 13 '24 Sale 30.00 1,020 30,600 115,156 Sep 16 04:17 PM VICKI LEE SATO Director Sep 13 '24 Proposed Sale 27.96 6,160 172,234 Sep 13 04:25 PM SATO VICKI L Director Sep 03 '24 Sale 25.00 3,080 77,007 116,176 Sep 04 06:26 PM Watts Ryan J. President and CEO Aug 20 '24 Sale 23.79 2,260 53,765 235,807 Aug 22 04:16 PM Krognes Steve E. Director Aug 20 '24 Sale 23.79 1,727 41,085 32,677 Aug 22 04:15 PM Schuth Alexander O. COFO and Secretary Aug 20 '24 Sale 23.65 5,806 137,286 180,613 Aug 22 04:14 PM Schuth Alexander O. COFO and Secretary Aug 21 '24 Sale 24.78 2,547 63,115 178,066 Aug 22 04:14 PM Ho Carole Chief Medical Officer Aug 21 '24 Sale 24.57 20,005 491,571 118,810 Aug 22 04:14 PM Ho Carole Chief Medical Officer Aug 20 '24 Sale 23.79 2,453 58,357 138,815 Aug 22 04:14 PM CAROLE HO Officer Aug 21 '24 Proposed Sale 23.65 20,005 473,118 Aug 21 04:42 PM ALEXANDER SCHUTH Officer Aug 21 '24 Proposed Sale 23.65 2,547 60,237 Aug 21 04:40 PM Krognes Steve E. Director Aug 20 '24 Proposed Sale 23.79 1,727 41,085 Aug 20 08:09 PM Schuth Alexander O. Officer Aug 20 '24 Proposed Sale 23.79 2,453 58,357 Aug 20 08:09 PM Watts Ryan J. Director Aug 20 '24 Proposed Sale 23.79 2,260 53,765 Aug 20 08:08 PM Ho Carole Officer Aug 20 '24 Proposed Sale 23.79 2,453 58,356 Aug 20 08:08 PM ALEXANDER SCHUTH Officer Aug 20 '24 Proposed Sale 23.95 3,353 80,304 Aug 20 04:27 PM Schuth Alexander O. COFO and Secretary Aug 13 '24 Sale 22.89 2,272 52,006 186,419 Aug 15 04:10 PM Ho Carole Chief Medical Officer Aug 13 '24 Sale 22.89 2,337 53,494 141,268 Aug 15 04:09 PM Schuth Alexander O. Officer Aug 13 '24 Proposed Sale 22.89 2,272 52,006 Aug 13 08:37 PM Ho Carole Officer Aug 13 '24 Proposed Sale 22.89 2,337 53,494 Aug 13 08:36 PM Krognes Steve E. Director Jul 01 '24 Sale 22.12 30,000 663,668 34,404 Jul 03 09:13 PM Krognes Steve E. Director Jun 13 '24 Sale 21.79 688 14,992 52,620 Jul 03 09:13 PM SATO VICKI L Director Jul 01 '24 Sale 22.14 3,080 68,204 119,256 Jul 03 09:13 PM Cook Jennifer E. Director Jun 06 '24 Sale 21.73 1,458 31,682 20,038 Jun 10 08:06 PM SATO VICKI L Director May 15 '24 Sale 20.39 1,674 34,133 116,369 May 17 04:28 PM SATO VICKI L Director Apr 15 '24 Sale 18.29 1,666 30,471 118,043 Apr 17 05:14 PM Krognes Steve E. Director Apr 01 '24 Sale 20.50 92,500 1,896,250 47,341 Apr 02 06:07 PM SATO VICKI L Director Mar 15 '24 Sale 20.10 1,666 33,487 119,709 Mar 19 04:27 PM SATO VICKI L Director Feb 15 '24 Sale 18.37 1,666 30,604 121,375 Feb 20 05:38 PM Krognes Steve E. Director Feb 13 '24 Sale 17.29 2,750 47,548 139,841 Feb 15 09:16 PM Watts Ryan J. President and CEO Feb 13 '24 Sale 17.29 9,589 165,794 238,067 Feb 15 09:15 PM Ho Carole Chief Medical Officer Feb 13 '24 Sale 17.29 2,784 48,135 145,010 Feb 15 09:14 PM Ho Carole Chief Medical Officer Feb 14 '24 Sale 17.79 1,405 24,995 143,605 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 14 '24 Sale 17.66 20,128 355,460 187,341 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 13 '24 Sale 17.29 2,716 46,960 207,469 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 08 '24 Option Exercise 0.68 50,000 34,000 210,185 Feb 12 04:48 PM SATO VICKI L Director Jan 16 '24 Sale 18.42 1,666 30,688 123,041 Jan 18 06:26 PM Ho Carole Chief Medical Officer Jan 10 '24 Sale 19.02 4,668 88,785 147,794 Jan 12 08:18 PM Watts Ryan J. President and CEO Jan 09 '24 Sale 19.78 7,818 154,640 2,268,363 Jan 11 05:28 PM Ho Carole Chief Medical Officer Jan 05 '24 Sale 19.43 9,972 193,756 198,777 Jan 09 07:35 PM Krognes Steve E. Director Jan 05 '24 Sale 19.43 3,208 62,331 142,591 Jan 09 07:34 PM Schuth Alexander O. COFO and Secretary Jan 05 '24 Sale 19.43 9,972 193,756 539,307 Jan 09 07:34 PM Watts Ryan J. President and CEO Jan 05 '24 Sale 19.43 17,483 339,695 2,276,181 Jan 09 07:33 PM SATO VICKI L Director Dec 15 '23 Sale 23.39 1,666 38,968 124,707 Dec 18 07:30 PM SATO VICKI L Director Nov 15 '23 Sale 19.13 1,666 31,871 126,373 Nov 16 06:14 PM SATO VICKI L Director Oct 16 '23 Sale 20.66 1,666 34,420 128,039 Oct 18 04:44 PM
Index -
P/E 19.79
EPS (ttm) 5.60
Insider Own 3.49%
Shs Outstand 62.26M
Perf Week 1.81%
Market Cap 6.84B
Forward P/E 5.14
EPS next Y 21.55
Insider Trans -0.30%
Shs Float 59.60M
Perf Month -3.15%
Income 394.92M
PEG 4.08
EPS next Q 5.52
Inst Own 94.82%
Short Float 3.17%
Perf Quarter 2.58%
Sales 3.91B
P/S 1.75
EPS this Y 6.74%
Inst Trans -0.78%
Short Ratio 2.70
Perf Half Y -10.75%
Book/sh 60.94
P/B 1.82
EPS next Y 10.38%
ROA 3.49%
Short Interest 1.89M
Perf Year -17.18%
Cash/sh 32.08
P/C 3.45
EPS next 5Y 4.85%
ROE 10.84%
52W Range 99.06 - 137.38
Perf YTD -9.95%
Dividend Est. -
P/FCF 6.55
EPS past 5Y -3.53%
ROI 4.42%
52W High -19.38%
Beta 0.57
Dividend TTM -
Quick Ratio 1.90
Sales past 5Y 15.52%
Gross Margin 73.60%
52W Low 11.81%
ATR (14) 2.66
Dividend Ex-Date -
Current Ratio 2.25
EPS Y/Y TTM 546.69%
Oper. Margin 16.63%
RSI (14) 51.46
Volatility 2.26% 2.23%
Employees 2800
Debt/Eq 1.54
Sales Y/Y TTM 3.91%
Profit Margin 10.10%
Recom 1.42
Target Price 178.29
Option/Short Yes / Yes
LT Debt/Eq 1.37
EPS Q/Q 70.48%
Payout 0.00%
Rel Volume 2.85
Prev Close 111.29
Sales Surprise 1.37%
EPS Surprise 7.68%
Sales Q/Q 6.95%
Earnings Jul 31 AMC
Avg Volume 700.63K
Price 110.76
SMA20 0.01%
SMA50 0.25%
SMA200 -3.50%
Trades
Volume 1,995,391
Change -0.48%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-24 Initiated
Goldman
Buy
$169
Jan-03-24 Initiated
Robert W. Baird
Outperform
$160
Nov-27-23 Downgrade
UBS
Buy → Neutral
$170 → $135
Sep-29-23 Initiated
Raymond James
Mkt Perform
Jun-12-23 Resumed
Wells Fargo
Equal Weight
$184 → $140
Dec-09-22 Upgrade
Goldman
Neutral → Buy
$192 → $190
Jun-14-22 Initiated
UBS
Buy
$194
Apr-06-22 Downgrade
Goldman
Buy → Neutral
$202 → $196
Nov-19-21 Resumed
Goldman
Buy
$198
Oct-07-21 Resumed
Jefferies
Buy
$172
Oct-05-21 Initiated
Citigroup
Buy
$200
Sep-23-21 Initiated
Needham
Buy
$220
May-19-21 Resumed
JP Morgan
Overweight
$183 → $206
Apr-07-21 Resumed
RBC Capital Mkts
Outperform
$186
Feb-05-21 Reiterated
H.C. Wainwright
Buy
$195 → $207
Feb-03-21 Upgrade
Piper Sandler
Neutral → Overweight
$150 → $175
Jan-29-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Dec-16-20 Initiated
UBS
Buy
$174
Nov-03-20 Reiterated
H.C. Wainwright
Buy
$185 → $195
Oct-09-20 Reiterated
H.C. Wainwright
Buy
$175 → $185
Show Previous Ratings
Sep-16-24 07:30AM
Sep-09-24 07:58AM
Sep-07-24 10:17PM
Sep-05-24 07:30AM
01:07AM
12:12AM
Loading…
Sep-04-24 12:12AM
Sep-03-24 07:00AM
Sep-02-24 06:05PM
Aug-30-24 11:31AM
01:16AM
Aug-23-24 10:13AM
(Pharmaceutical Technology)
Aug-22-24 04:05PM
Aug-21-24 04:15PM
Aug-06-24 09:55AM
09:40AM
04:06PM
Loading…
Aug-05-24 04:06PM
09:15AM
Jul-31-24 10:36PM
05:45PM
04:40PM
(Associated Press Finance)
04:05PM
Jul-29-24 06:00AM
Jul-25-24 04:05PM
Jul-24-24 10:01AM
Jul-23-24 03:52AM
Jul-22-24 07:45AM
Jul-19-24 01:58PM
Jul-17-24 04:15PM
Jul-11-24 08:30AM
Jul-09-24 07:45AM
08:09AM
Loading…
Jul-04-24 08:09AM
Jul-01-24 12:16AM
Jun-26-24 02:11PM
Jun-25-24 03:39PM
Jun-21-24 07:00AM
06:33AM
Jun-20-24 04:08PM
(Investor's Business Daily)
10:08AM
(Investor's Business Daily)
07:45AM
Jun-14-24 06:13AM
Jun-11-24 10:42AM
Jun-03-24 02:27PM
Jun-01-24 08:05AM
May-31-24 11:31AM
May-30-24 07:30AM
May-29-24 04:15PM
07:45AM
May-28-24 07:00AM
May-26-24 10:09AM
May-23-24 06:00AM
May-22-24 07:01PM
04:00PM
May-17-24 02:32PM
May-09-24 09:19AM
May-08-24 04:30PM
01:22PM
May-07-24 05:37PM
10:57AM
May-06-24 09:29AM
May-03-24 12:41PM
11:49AM
May-02-24 11:26AM
03:53AM
May-01-24 08:56PM
07:00PM
04:24PM
(Associated Press Finance)
04:10PM
04:05PM
Apr-30-24 09:50AM
Apr-24-24 04:05PM
10:01AM
05:21AM
Apr-23-24 11:15AM
Apr-17-24 04:15PM
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Apr-02-24 07:30AM
Mar-29-24 11:30AM
Mar-28-24 10:15AM
Mar-20-24 10:15AM
Mar-18-24 03:28PM
Mar-17-24 08:50AM
Mar-14-24 12:00PM
10:00AM
Mar-13-24 02:25PM
Mar-12-24 05:34PM
04:15PM
Mar-09-24 11:15AM
Mar-07-24 01:51PM
01:10PM
(Thomson Reuters StreetEvents)
10:08AM
Feb-29-24 10:45AM
10:35AM
Feb-28-24 06:30PM
05:20PM
04:33PM
04:29PM
(Associated Press Finance)
04:05PM
Feb-27-24 10:15PM
(Thomson Reuters StreetEvents)
07:45AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Henderson Mary Elizabeth SVP, Technical Operations Sep 06 '24 Sale 108.30 1,410 152,703 14,531 Sep 11 11:38 AM Henderson Mary Elizabeth Officer Sep 06 '24 Proposed Sale 110.00 2,691 296,010 Sep 05 07:50 PM Winningham Rick E Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:57 PM Smith Mark Douglas Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:55 PM RIEDEL NORBERT G Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:49 PM ORiordan Anne Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:42 PM O'Keefe Kenneth W Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:35 PM McSharry Heather Ann Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:29 PM Cook Jennifer E. Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:19 PM Sohn Catherine A. Director Aug 05 '24 Proposed Sale 111.00 3,075 341,325 Aug 02 04:20 PM Carr Patricia SVP, Chief Accounting Officer Jun 07 '24 Sale 108.83 163 17,738 6,596 Jun 11 08:15 PM Patil Neena M EVP & Chief Legal Officer May 03 '24 Sale 109.65 5,000 548,250 36,629 May 07 05:31 PM Carr Patricia SVP, Chief Accounting Officer Mar 06 '24 Sale 119.64 1,936 231,628 8,364 Mar 08 06:07 PM Carr Patricia SVP, Chief Accounting Officer Mar 07 '24 Sale 116.98 1,768 206,821 6,596 Mar 08 06:07 PM Johnson Philip L EVP & Chief Financial Officer Mar 01 '24 Buy 119.65 12,000 1,435,800 27,932 Mar 05 07:28 PM Smith Mark Douglas Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:39 PM Cook Jennifer E. Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite